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Abstract 
The binding interactions of two antitumour agents that target the paclitaxel site, docetaxel and 
discodermolide, to unassembled -tubulin heterodimers and microtubules have been studied 
using biochemical and NMR techniques. The use of discodermolide as a water-soluble 
paclitaxel biomimetic and extensive NMR experiments allowed the detection of binding of 
microtubule-stabilizing agents to unassembled tubulin -heterodimers. The bioactive 3D 
structures of docetaxel and discodermolide bound to -heterodimers were elucidated and 
compared to those bound to microtubules, where subtle changes in the conformations of 
docetaxel in its different bound states were evident. Moreover, the combination of 
experimental TR-NOE and STD NMR data with CORCEMA-STD calculations indicate that 
docetaxel and discodermolide target an additional binding site at the pore of the microtubules, 
which is different from the internal binding site at the lumen previously determined by electron 
crystallography. Binding to this pore site can then be considered as the first ligand-protein 
recognition event that takes place in advance of the drug internalization process and 
interaction with the lumen of the microtubules. 
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Introduction. 
The discovery of natural products that attenuate cell growth by acting as inhibitors of cellular 
microtubules has resulted in the development of clinically-important drugs in cancer 
chemotherapy(1-3). A particularly valuable class of such antimitotic compounds preferentially 
binds to assembled microtubules over unassembled tubulin, thus stabilizing the polymer and 
impairing the dynamics. Through this mechanism of action, the dividing tumour cells become 
blocked in the G2/M phase of the cell cycle resulting in apoptosis. These microtubule-
stabilizing agents (MSAs) can be classified into two groups, depending on their competition for 
three distinct known microtubule-binding sites. The first group includes paclitaxel and its 
biomimetics (docetaxel, epothilones, discodermolide, dictyostatin, cyclostreptin, etc.)(4). These 
molecules competitively bind to one or both binding sites present in the lumen (internal site of 
the tubulin -subunit) and at the pore of the microtubules (external site, involving the  and  
subunits of different heterodimers). It is proposed that these ligands bind to this external site 
and this facilitates transport to the luminal site. In support of this hypothesis, a fluorescent 
taxoid (hexaflutax) was able to bind only to the external site on microtubules. It was shown that 
binding to this pore site was sufficient to induce microtubule assembly(5),(6). Moreover, the 
binding of cyclostreptin (a MSA that covalently binds tubulin) with microtubules was 
characterized by mass spectrometry, showing that this ligand binds to both the inner and the 
pore sites (7). 
At present, it is not yet established if microtubule-stabilizing agents that target the paclitaxel 
binding site bind only to the inner, only to the outer, or to both binding sites. However, their 
strict 1:1 stoichiometry with respect to the -tubulin heterodimer indicates that binding to 
both sites is mutually exclusive(4,8-9). Furthermore, indirect evidence supports the presence 
of a binding site with moderate affinity for MSAs. It is known that fast kinetics of dissociation in 
the relaxation time scale are required to observe TR-NOESY signals. As it was possible to 
obtain strong TR-NOESY signals of docetaxel and discodermolide bound to microtubules(10), 
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it is likely that a binding site with a lower affinity than the luminal binding site is also involved in 
the recognition of these compounds.  
The second group of microtubule-stabilizing agents includes laulimalide and peloruside, which 
compete for a different binding site that has not yet been fully characterized(11,12).  
Microtubule structure determination both in the presence and in the absence of MSAs remains 
a challenge for structural biology. The complexity of this system, where different aggregation 
states of the -heterodimer can coexist in solution, has precluded the crystallization of 
microtubules. Therefore, only 4 Å resolution X-ray structures of RB3-tubulin complexes are 
available(13). Moreover, only a few drugs that target tubulin have been crystallized with the 
protein, also leading to relatively limited resolution (3.5 Å) structures(14,15). 
In 1998, Nogales et al. reported the first structural data for tubulin in the presence of a 
microtubule-stabilizing agent(16). The structure of Zn-stabilized tubulin sheets in the presence 
of paclitaxel was determined by electron crystallography, which enabled the location of the 
paclitaxel binding site within the tubulin -subunit, establishing interactions with residues at the 
H6-H7 loop, H7 helix, B7-H9 M-loop and B9-B10 loop. However, the resolution of the structure 
precluded the complete characterization of the ligand bound conformation, and additional 
computational studies were needed to refine the ligand orientation and elucidate the key drug-
protein interactions(17). Subsequently, Nettles et al. reported the structure of the complex of 
epothilone A bound to zinc-stabilized tubulin sheets by electron crystallography(18). This work 
confirmed that the binding site of this paclitaxel mimetic was located within the same region of 
the tubulin -subunit as the paclitaxel site previously described by Nogales. Despite these 
findings, the aggregation state of this system (Zn-induced sheets) lacks the interprotofilament 
interactions present in microtubules and, therefore, the precise mapping of the binding site of 
taxoids and paclitaxel mimetics to microtubules, as well as a detailed knowledge of the 
molecular recognition process, remains elusive. 
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In this context, we have focused on determining the binding modes of docetaxel and 
discodermolide to microtubules in aqueous solution by using an integrated NMR and 
computational approach. Since the action of these molecules probably involves a multistep 
mechanism, with different recognition events, we have also studied the binding of these two 
paclitaxel mimetics to the non-polymerized tubulin heterodimer, in order to check if the 
protein is able to recognize the drugs in this non-aggregated state. Although this event seems 
to be an essential step for the promotion of microtubule formation from tubulin -
heterodimers by MSA(19), as far as we know, there is no direct biochemical evidence in 
support of the binding of paclitaxel and its biomimetics to unassembled tubulin. 
In previous work, the use of cyclostreptin, a drug that covalently binds to tubulin, allowed the 
detection of a weak interaction with non-polymerized tubulin -heterodimers at the external 
pore site(7). This region had been predicted to be the transient location for paclitaxel in its way 
towards the luminal site(5,20). Surprisingly, cyclostreptin was found to bind to polymeric 
tubulin both at the inner luminal and at the pore site. However, for non-polymerized tubulin 
-heterodimers, it was only bound to the pore site, thus providing the first direct identification 
of those residues of the external site present in unassembled tubulin. In contrast, the luminal 
site has been proposed as the binding site on the basis of docking and INPHARMA analysis of 
epothilones bound to unpolymerized tubulin(21). 
Herein, we provide experimental evidence for the binding of docetaxel and discodermolide to 
unassembled tubulin. These compounds promote tubulin polymerization under conditions in 
which tubulin itself is not able to undergo assembly, i.e. with GDP bound to the exchangeable 
site(8). These results imply that paclitaxel mimetics not only stabilize the microtubule when it is 
already formed but also can promote microtubule formation. In this work, two key questions 
related to the mechanism of recognition and stabilization of tubulin by MSA are addressed: the 
number and location of the binding sites involved in the drug recognition event by 
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microtubules, and the characterization of the binding of these MSAs to non-polymerized 
tubulin. 
 
Results. 
Characterization of the binding of the MSAs to non-polymerized states of the protein. Binding 
of discodermolide to tubulin -heterodimer. 
Microtubule-stabilizing agents induce microtubule assembly under conditions in which tubulin 
itself is unable to assemble (GDP-bound and absence of magnesium). Therefore, it is likely 
that they bind to unassembled tubulin -heterodimer. In practice, the binding of paclitaxel 
and docetaxel to tubulin in the absence of Mg2+ has been previously studied(19), using 
concentrations up to 10 μM of paclitaxel and 50 μM of docetaxel. However, under these 
conditions, no binding was detected, indicating that the limit for the dissociation constant 
should be in the millimolar range. In recent years, structurally novel microtubule-stabilizing 
agents with better solubility and higher affinity for microtubules, as is the case for 
discodermolide, have been discovered. Thus, higher concentrations of these ligands can be 
assayed for tubulin binding. The centrifugation assays indicated that discodermolide 
cosediments with the non-polymerized tubulin -heterodimer in the absence of Mg2+ 
(conditions in which tubulin is not polymerized(22)). However, given the low binding 
affinity observed (in the range of 104 M-1), it was not possible to reach saturation at the 
maximum possible ligand concentrations and the stoichiometry of the interaction could not be 
quantified. Nevertheless, since Scatchard analysis of the data indicates 0.85±0.22 sites, we 
have assumed a 1:1 stoichiometry for the interaction which results in a binding constant of 
2.0±0.7x104 M-1 (Figure 1). 
In order to check the specificity of the process, competition experiments were performed. In 
particular, discodermolide and epothilone B, at 55 μM concentrations, were incubated,  both 
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separately and together, in D2O with 45 μM tubulin in 10 mM NaPi, 0.1 mM GTP and pH* 7.0. 
While 0.35 mol epothilone B and 0.17 mol discodermolide per tubulin mol were found to be 
bound to tubulin when the ligands were incubated separately, the stoichiometries were 
reduced to 0.21 and 0.09 respectively when the ligands were incubated together. This result 
indicates that they compete (at least partially) for the same site. Control repeats in H2O of the 
corresponding experiments gave the same results. 
Purified tubulin is an unstable protein known to rapidly denature in aqueous solution. D2O has 
been reported to stabilize tubulin against deactivation and aggregation(23), as well as to 
stabilize protein assemblies, including microtubules(24). In order to determine the 
oligomerization state of tubulin in our experiments, and to rule out any possible changes due 
to the presence of D2O or to ligand binding, samples containing 13 and 45 μM tubulin in 10 
mM NaPi, 0.1 mM GTP in D2O, pH* 7.0, at 25 ºC, were analyzed by sedimentation velocity in 
an analytical ultracentrifuge. These samples were found to contain over 90% of 5.8 S 
tubulin heterodimers, two hours after equilibration in the D2O buffer. Incubation with 55 
μM docetaxel or discodermolide did not induce tubulin -heterodimer aggregation under 
these experimental conditions. Thus, the non-polymerized state of the tubulin -heterodimer 
was confirmed. 
 
Conformation of microtubule-stabilizing agents bound to non-polymerized tubulin -
heterodimer and microtubules. 
The bound conformation of docetaxel and discodermolide to the tubulin -heterodimer was 
deduced by analysis of the TR-NOESY cross peaks, as shown in Figs 2A and 2B respectively 
(Expanded versions are shown in Supplementary figures 2 and 3 respectively). Extremely 
weak NOEs were evident between both aromatic moieties (2-OBz and 3'-Ar), resembling the 
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results obtained for docetaxel bound to microtubules(25). These data indicate that the so-
called "polar conformation" is not significantly populated in the bound state. 
In contrast, strong NOEs were detected between the 4-OAc methyl group and both aromatic 
rings. The tert-butoxy protons also showed clear NOE contacts with both aromatic rings, 
although significantly weaker than those detected for the 4-OAc group. Notably, this result 
contrasts with the observations described for docetaxel when bound to microtubules(25). In 
that case, the NOEs between the tert-butoxy and 2-OBz meta protons were significantly 
stronger than those between the 2-OBz meta protons and the 4-OAc group. The ratio of NOE 
intensities between the key proton pairs was estimated. Thus, the intensity of the Hmeta 2-
OBz (two protons)-tert-butoxy (nine protons) cross peak was compared to that between the 
Hmeta 2-OBz (two protons)-4-OAc (three protons) equivalent. The corresponding ratio clearly 
changed from 2.1 to 1.3, when the NOESY spectra recorded in the presence of microtubules 
was compared to that with non-polymerized tubulin -heterodimer. This change in intensity 
ratio could be correlated with a change in the conformation and thus in the relative orientation 
of the key pendant groups. Furthermore, the data suggest that the non-polymerized tubulin 
-heterodimer-bound conformation of docetaxel presents a more open arrangement 
between the hydrophobic groups (2-OBz and tert-butoxy) than that adopted when it is bound 
to microtubules (Figure 2C).  
The analysis of the molecular modeling results permitted the determination of the docetaxel 
conformation bound to non-polymerized tubulin -heterodimer with the best fit to the NMR 
data as defined by improper torsion angle values for O-C2-C3´-NBz (1) and O-C2-C3´-C(Ph) 
(2) of 98 and -40º, respectively.  In contrast, the corresponding torsion angles are 77 and -80º 
for the docetaxel conformation bound to microtubules. Therefore, the microtubule bound 
docetaxel conformation as deduced by NMR is intermediate between the so-called T-paclitaxel 
geometry, described by Snyder et al.(17) (defined by80 and -58) and the non-polar 
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geometry (with improper torsion angles 42, -85). On the other hand, the docetaxel 
conformation bound to non-polymerized tubulin -heterodimer approximates closely to the T-
paclitaxel conformation(17).  
In contrast, the REDOR-based paclitaxel conformation(26) does not account for the observed 
NOEs under our experimental conditions, neither for dimeric tubulin, nor for microtubules. The 
REDOR-based conformation displays the C3´ aromatic ring attached to the amide moiety 
pointing out to the opposite direction of the taxane ring, far apart from the 2-OBz aromatic ring. 
This geometry cannot satisfy the observed NOE contacts between tert-butoxy and 2-OBz 
protons.  
On the other hand, no significant differences were found between the conformation of 
discodermolide when bound to non-polymerized tubulin -heterodimer or to microtubules. 
Thus, for discodermolide, the bound conformation in both states corresponds to that previously 
described(10).  
 
Saturation Transfer Difference (STD) analysis of compounds bound to non-polymerized tubulin 
-heterodimer and to microtubules. 
 In order to gain insight into the mechanisms employed by microtubule-stabilizing agents to 
induce microtubule assembly, the binding of these compounds to non-polymerized tubulin -
heterodimer and to microtubules was studied using Saturation Transfer Difference analysis. 
STD-NMR experiments detect magnetization transfer from a given protein to a bound ligand. 
Only bound ligands show STD signals and, as in any NOE-type experiment, the observed STD 
effect depends on the distance between the protein and ligand protons, thus providing a useful 
tool to detect the ligand epitope and to probe the pharmacophore region. Additionally, STD 
also depends on the exchange rate, binding affinity, concentrations of ligand and receptor, 
rotational correlation times, and spectrometer frequency. Binding of docetaxel and 
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discodermolide to non-polymerized tubulin -heterodimer in D2O, 10 mM NaPi, 0.1 mM GTP 
and pH* 7.0 could be easily detected by STD (Figure 3A-B). The addition of an excess of 
discodermolide to a sample containing tubulin and docetaxel reduced the characteristic STD 
signals of docetaxel, (the peak at 7.50 ppm for the 3´-Ar protons is shown as example in 
Figure 3C). This result indicates that they compete, at least partially, for the same binding site, 
as also deduced from the ultracentrifugation experiments (see above). However, given the 
difference of more than one order of magnitude between the estimated binding constants for 
those molecules (ca. 2.0x104 M-1 for discodermolide and less than 1x103 M-1 for docetaxel 
(19)), an even more drastic decrease of the docetaxel STD signals in the presence of 
discodermolide would have been expected. This finding suggests the presence of additional 
binding sites for docetaxel binding (see below for further discussion). 
The comparison of the STD profiles of docetaxel bound to unassembled tubulin and to 
microtubules allowed us to identify those protons which are closer to the protein in each 
aggregation state of the system. It can be observed (Figure 3D) that the profiles are similar, 
although not identical. As expected, the absolute value of the detected STD effect on 
docetaxel protons was higher in the presence of microtubules. This result merely reflects that 
the ligand is bound to a larger receptor in the case of microtubules. In both cases, the protons 
with the higher STD values were the aromatic ones of the groups at positions 2 and 3’. 
In the case of discodermolide, STD effects have smaller values than the ones for docetaxel. In 
addition, the effects are quite uniform within the molecule for both microtubules and non-
polymerized tubulin -heterodimer samples. The protons with the highest STD effect are 
H11 and 25-CH3 in the presence of microtubules and H2, H11 in the case of unassembled 
tubulin heterodimers. 
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Modeling of the bioactive conformations in the binding sites. 
The NMR data obtained were then employed to model the tubulin-bound conformations of 
discodermolide and docetaxel. First, docking of the ligands in the luminal binding site 
(1JFF)(27) was performed, as previously described(10). The resulting docetaxel binding mode 
at the luminal site (Figure 4A) was fairly similar to that reported for paclitaxel using electron 
crystallography, as shown in Figure 4B. The discodermolide binding model involving the 
luminal binding site has already been described in our previous work (10). 
Additional docking calculations were also performed for the pore site. Initially, the model 
described by Magnani and co-workers was employed,(28). In this case, two binding modes 
were found (Figure 5A). In the first one, docetaxel was placed between the tubulin -subunit, 
close to the luminal site (1, following the Magnani nomenclature), and the -subunit of the 
next dimer in the protofilament (2, see Figure 5A, cyan structure). In this case, the location of 
the binding site was similar to that described by Magnani. However, the binding pose of 
docetaxel was rather different to that described by Magnani for the paclitaxel analogue 
Hexaflutax. This discrepancy could be due to the different chemical nature of the ligand side 
chains at C13 and/or to the different docking protocols employed. Magnani treated paclitaxel 
as a flexible entity, searching for the best pose with no experimental constraints. In contrast, 
we considered the experimental NOE-based docetaxel conformation for the docking protocol. 
In the second solution, docetaxel was bound in the bottom part of the pore, close to subunits 
1 and 4 (see Figure 5A, magenta structure), in a similar location to that described by 
Freedman et al.(29) However, as in the former case, the obtained binding pose of the ligand 
relative to this site was different to that described by Freedman.  
Docking of discodermolide to the pore site (the geometries of the bound conformers to non-
polymerized tubulin -heterodimers and to microtubules are essentially identical) resulted in 
12 
 
a preference for the ligand to occupy the lower part of the pore (Figure 5B), near subunits 1 
and 4, as described above for the second solution found for docetaxel. 
 
Corcema-ST calculations 
A) Paclitaxel mimetics bound to microtubules 
The theoretical STD profiles of the docking models described above were calculated by using 
the CORCEMA-ST program and compared to the experimental data. In the case of 
microtubules, the best fit between the experimental and calculated STD values was obtained 
when the docking solutions located at the pore site were considered (Figure 5A).  For 
docetaxel, the blue conformer (Figure 5A) provided the best fitting (Figure 6A), with a 
NRMSD=9.9%. In contrast, the pink structure at the pore (Figure 5A) and the geometries 
docked at the internal site (Figure 4A) did not satisfactorily reproduce the experimental data 
(see Figure S1 in the supplementary material. Values of NRMDS=56.5% and NRMSD=42.6% 
were found, respectively). 
In the best binding pose (STD- and trNOESY-based), the tert-butoxy group of docetaxel is 
located in the proximity of the CH3 groups of the side chains of  1 T220 and  1 T221. In fact, 
T220 is the nucleophile residue that reacts with cyclostreptin and this peptide is protected for 
hydrogen/deuterium exchange (HDX) in paclitaxel induced microtubules  (30). The hydroxyl 
group at position 7 of docetaxel is engaged in hydrogen bonds with 1 E207 and 1 K176 
(also protected from HDX, while the aryl group at the C13 side chain occupies the hydrophobic 
pocket close to 1 Y210 and to the CH3 of 1 T223. The benzoyl group of docetaxel is located 
in the vicinity of the CH3 of 2 A289. 
In the case of discodermolide bound to microtubules, the best fit between the experimental 
NMR data and the docking solutions (Figure 6B NRMSD = 22.4%) was found for the pore site. 
In this case, the C11 hydroxyl of discodermolide is engaged in two hydrogen bonds with 
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residues 1 K216 and 1 F212, while the C7 hydroxyl forms a hydrogen bond with 1 T220. 
One additional hydrogen bond is established between the 4 V93 backbone carbonyl and the 
hydroxyl moiety at position 17. Me30 is close to 4 F92, while the carbamate moiety of the 
ligand forms a hydrogen bond with the backbone carbonyl group of 4 F94.  The docked 
solutions located at the internal site provided a much poorer fit with the STD experimental 
data, as deduced from the high NRMSD = 61.6%. 
Therefore, the combined NMR/docking protocol employed herein provides support for the 
major binding site of both paclitaxel mimetics docetaxel and discodermolide bound to 
microtubules to be located at the pore of the microtubules. 
 
B) Paclitaxel mimetics bound to non polymerized tubulin  heterodimers. 
First, it is important to note that the observed STD signals obtained with unassembled tubulin 
-heterodimer preparations cannot be due to interactions with the complete pore site. 
Indeed, this cavity is only present in microtubules since it is formed by interactions of different 
heterodimers. Therefore, in order to obtain a structural view of the interaction of the paclitaxel 
mimetics with a partially formed pore, additional docking models were evaluated. The first 
model employed contained only the 1 subunit. This is the region that provided the best fit 
between the experimental NMR and the CORCEMA–ST predictions for microtubules, as 
described above (blue structure, Figure 5A). A second model was also calculated by 
considering only the 4 subunit, which shows major interactions with the C13 side chain of 
docetaxel, at the pore site (pink structure, Figure 5A). Additional models of docetaxel and 
discodermolide bound to tubulin -heterodimer in the internal binding site were also 
evaluated.  
Altogether, the fitting procedures between the experimental data and the CORCEMA–ST 
calculations were carried out evaluating the three putative binding sites – the internal binding 
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site, the external semi-site at 1, and the external semi-site at 4. The theoretical STD effects 
calculated for docetaxel bound at the internal binding site (red thin line in Figure 7A) provided 
a fair agreement with those experimentally observed in the presence of non-polymerized -
tubulin heterodimer, NRMSD=22.1%. However, some protons in this model produced STD 
values higher than those experimentally observed (o-Ar, m-Ar, p-Ar and H7). Alternatively, the 
docking pose at the 1 semi-site also provided a reasonable fit to the observed STD profile for 
the taxane core protons, NRMSD=25.5%  (green thin line in Figure 7A), but failed to reproduce 
the STD profile of most of the protons at the C13 side chain, including those of the aryl and 
benzoyl rings.  Finally, the calculated STD profile for the partially formed pore site at 4 gave a 
poor fit with the experimental data, NRMSD=40.16% (Supplementary Figure 1B). Thus, no 
single solution gave a satisfactory match with all the experimental STD data. In practice, a 
linear combination between the STD values obtained for the luminal binding site with those 
obtained from the partially formed pore site at 1 gave the best agreement with the 
experimental data (NRMSD=16.7% dashed line Figure 7A). 
For discodermolide, neither the previously reported docking model at the luminal site, 
NRMDS=27.6 % (red thin line in Figure 7B) (10), nor the partially formed pore bound 
structures, NRMDS=55.5 % (green thin line in Figure 7B) provided a good fit between the 
calculated and the experimental STD values. As for docetaxel, a linear combination between 
the STD profiles calculated for both possible binding poses resulted in the best fit, with a 
NRMSD= 19.5 %. 
 
Discussion 
Although ligand binding to unassembled tubulin is essential for explaining the mode of action 
of microtubule-stabilizing agents(4,9,19), the unequivocal experimental demonstration of its 
existence has proved elusive. Indeed, it has only been previously observed by covalent 
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labeling of the pore site(7) employing cyclostreptin. Up to now, the reversible interaction of 
microtubule-stabilizing agents with -tubulin heterodimer in its non-polymerized state had 
never been directly observed.  In order to stabilize microtubules, it is required that the binding 
affinity of the compound for the assembled state is much higher than that for the unassembled 
form, thus displacing the assembly equilibrium towards the polymer. Therefore, the existence 
of low affinity of MSAs for unassembled -tubulin heterodimers can be predicted. This low 
affinity precluded the previous detection of binding of MSAs to non-polymerized -tubulin 
heterodimers using centrifugation techniques(19). Notably, in the present work, the use of TR-
NOESY and STD experiments with discodermolide as microtubule-stabilizing agent, with 
higher aqueous solubility, has allowed the first experimental detection of binding to non-
polymerized tubulin -heterodimers, as well as the biochemical and structural 
characterization of the interaction. 
Two different binding sites in microtubules have been described for paclitaxel biomimetics, the 
pore site to which binding of cyclostreptin(7) and hexaflutax(6) take place, and the internal 
luminal site, where paclitaxel itself interacts(16,31). When microtubules are formed, it is 
expected that paclitaxel and its mimetics should be mostly bound to the high affinity luminal 
site. In principle, the existence of a very high affinity site precludes the use of ligand-based 
NMR techniques for monitoring interactions, such as TR-NOESY and STD, due to the 
requirements of fast dissociation rate of the ligands for these experiments to succeed. 
Therefore, it is highly probable that the binding events associated with this high affinity luminal 
site are TR-NOESY- and STD-silent. However, these experiments produced clear-cut NMR 
signals for discodermolide and docetaxel in the presence of microtubules. Therefore, it seems 
very likely that the observed TR-NOESY and STD signals arise from an alternative binding 
event, probably a pre-release conformation. In practice, the best fitting of the experimental 
STD effects to distinct binding mode geometries was obtained when the interaction of the 
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ligands to the pore site was considered, suggesting that the experimental NMR signals of 
paclitaxel mimetics bound to microtubules arise from the ligand that has been just released 
from the microtubules. This final release step complies with the kinetic requirements of TR-
NOESY and STD, because it should be fast enough in the relaxation time scale.  
Thus, according to our experimental data, MSAs bind and dissociate from/to microtubules 
following a two-step mechanism.(32) The first binding event is assigned to the binding to the 
external pore site(7), from which the dissociation kinetics is fast(32). The second, the slow 
step, should be the internalization towards the luminal site. Subsequently, in the dissociation 
process, the events are reversed. The first is the slow step, assigned to the transportation from 
the internal luminal to the external pore site, while the second fast step corresponds to the 
release of the ligand to the medium. This mechanism implies that the final release step of 
MSAs from microtubules takes place from the pore. Alternatively, the two steps involved in 
binding could be due to a conformational rearrangement of the luminal site, resulting in the 
release of the ligand by diffusion to the medium through the ends of the microtubule. However, 
this diffusion process should be expected to be rather slow(33,34) and, therefore, not 
compatible with the observed fast release of radioactive paclitaxel and docetaxel from 
assembled microtubules. It has been demonstrated that this phenomenon occurs within two 
minutes(35) and that the rate limiting step is the first slow step of dissociation. 
The analysis of the NMR data has indicated the existence of structural differences in the 
bioactive conformations of docetaxel when bound to microtubules versus non-polymerized 
-tubulin heterodimer. The resulting 3D models of the ligand-protein complexes (combining 
docking and CORCEMA-ST calculations) indicated that H229 of the tubulin -subunit at the 
luminal site, which simultaneously interacts with the 2-OBz and the C13 side chain in the 
internal binding site, and therefore makes them spatially separated (Figure 4), does not play 
any key role in the recognition process at the pore site. Indeed, the corresponding 
experimental NOEs between the meta protons of the 2-OBz moiety and the tert-butoxy protons 
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at the C13 side chain are significantly different when the TR-NOESY spectra of docetaxel are 
recorded in the presence of microtubules or non-polymerized -tubulin heterodimer. 
Therefore, the combined NMR/modelling data strongly suggest that, when microtubules are 
employed, it is the pore site that is observed by TR-NOESY and STD.  
With this information in hand, there is still the question of the actual site (or sites) that is 
interacting with docetaxel in non-polymerized -tubulin heterodimers. Thus, the experimental 
data were analyzed and compared to the predictions of CORCEMA-ST for all the possible 
binding sites described above. The best fit was obtained when the internal binding site was 
considered, indicating that this is the most plausible binding site for docetaxel in unassembled 
tubulin (Figure 4). Nevertheless, the fit between the experimental and predicted data 
considerably improved when the contribution of the 1 semi-site was additionally considered. 
In fact, the co-existence of two binding sites is in agreement with the observations of the 
competition experiments which suggested the existence of two simultaneously binding sites for 
dimeric tubulin. Thus, at the initial stages of the process, and when no polymer has been yet 
formed, these paclitaxel mimetics mainly interact at the luminal and 1 binding sites, which 
then further evolves to form the complete pore binding site. 
The results presented in this work have allowed the detection of the interaction of docetaxel 
and discodermolide with non-polymerized -tubulin heterodimers. The interaction has been 
biochemically characterized, clarifying the manner in which microtubule-stabilizing agents 
induce microtubule assembly from  -heterodimers. These data show that MSAs play a dual 
role since they not only stabilize microtubules once they are formed, but also promote tubulin 
polymerization. In addition, the bioactive conformations and the binding epitopes for docetaxel 
and discodermolide when bound to non-polymerized -tubulin heterodimers have been 
determined by NMR. Moreover, the binding epitopes of these compounds when bound to 
microtubules have been also described by using STD data.  CORCEMA-ST calculations were 
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carried out taking into account the two possible binding sites located at the pore and at the 
lumen of microtubules to discriminate among the different binding poses. The observed NMR 
findings can be satisfactorily explained by binding of these MSAs at the pore of the 
microtubules. The existence of this interaction mode therefore suggests that the recognition 
process of docetaxel and discodermolide by microtubules takes place following a two step 
mechanism. First, binding to the pore occurs, and then internalization to the lumen takes 
place. 
Finally, the existence of conformational variations in the bound geometry of docetaxel when 
bound to microtubules and to non-polymerized tubulin -heterodimers has been shown. 
These observations suggest that the binding of microtubule-stabilizing agents to the tubulin 
-heterodimer mainly involves the region where the luminal binding site in microtubules will 
be located. However, the partially formed pore site also participates in ligand recognition. 
 
Methods 
Proteins and ligands 
Purified calf brain tubulin and chemicals were obtained as previously described(8,36). 
Docetaxel (Taxotere) (Figure 1) was kindly provided by Rhône Poulenc Rorer, Aventis 
(Schiltigheim, France). Discodermolide (Figure 1) was synthesized as described(37). All 
compounds were diluted in 99.8% D6-DMSO (Merck, Darmstad, Germany) to a final 
concentration of 20 mM and stored at -20 ºC.  
 
Binding of microtubule-stabilizing agents to non-polymerized tubulin -heterodimers.  
The binding of microtubule-stabilizing agents to unassembled tubulin heterodimers was 
determined by centrifugation. Samples containing 50 μM discodermolide in D2O containing 10 
mM sodium phosphate, 0.1 mM GTP pH*(38) 7.0  (or the same buffer in H2O pH 7.0) were 
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incubated with increasing concentrations of tubulin up to 40 μM at 25 ºC. The samples were 
centrifuged at 100.000 rpm in a TLA 100.2 rotor in a Beckman Optima TLX ultracentrifuge for 
120 minutes. The upper and lower 500 μl were carefully collected, and the pellets were 
resuspended in 10 mM sodium phosphate, 0.1 mM GTP buffer pH 7.0, the concentration of 
tubulin in both parts of the tube and in the pellet were determined spectrophotometrically, 
using an extinction coefficient of 107000 M-1 cm-1 at 275 nm, in 10 mM phosphate buffer 1% 
SDS(39), by employing a Thermo Evolution 300 LC spectrophotometer. To 300 μl of each 
sample, 10 μM docetaxel was added as internal standard. The samples were extracted three 
times with an excess volume of dichloromethane, dried in vacuum and redissolved in 25 μl of 
60% methanol. The amount of discodermolide in the samples was analyzed in an Agilent 1100 
HPLC, employing a Zorbax Eclipse XDB-C18 developing a gradient from 60 to 70% methanol 
in water at 1 ml/min (5 min 60% 15 min gradient 5 min 70%).  
 
Analytical ultracentrifugation. 
The oligomerization state of the tubulin samples for the NMR experiments was analyzed by 
sedimentation velocity  in a Beckman Optima XL-I analytical ultracentrifuge (Beckman Coulter, 
Inc., Fullerton, CA) equipped with interference and absorbance optics, using an An50Ti rotor 
and double sector cells, at 43,000 or 50,000 rpm, 25 ºC. The differential sedimentation 
coefficient distributions, c(s), were calculated by least squares boundary modeling of 
sedimentation velocity data using the program SEDFIT(40-41). The weight average 
sedimentation coefficient values measured in the D2O buffer at 25 ºC were  corrected for 
solvent composition and temperature to H2O at 20 ºC,  s20w, using  SEDNTERP, retrieved 
from the RASMB server(42). 
 
 
 
20 
 
NMR sample preparation and experiments 
The samples of the ligands bound to non-polymerized tubulin -heterodimers were prepared 
in 200 L NMR tubes using a 300 μM concentration of the desired compound and 10 μM of 
tubulin in D2O, 10 mM NaPi, 0.1 mM GTP pH* 7.0. The tubulin samples were prepared by 
removing sucrose, Mg2+, and H2O from the storage buffer of a 10 mg sample of frozen tubulin, 
by chromatography using a Sephadex G-25 medium column (25x0.9 cm) equilibrated in D2O, 
10 mM NaPi, 0.1 mM GTP pH* 7.0. Tubulin was centrifuged for 10 minutes at 50.000 in a 
TLA120 rotor in an Optima TLX centrifuge to remove aggregates, and its concentration was 
determined spectrophotometrically by employing an extinction coefficient of 107000 M-1 cm-1 in 
10 mM phosphate buffer containing 1% SDS(39). The samples were incubated at 25 ºC for 30 
min prior to measurement. 
The samples of the ligands bound to microtubules were prepared in 200 L NMR tubes using 
a 300 μM concentration of the desired compound and 20 μM of tubulin in D2O, 10 mM KPi, 0.1 
mM GMPCPP, 6 mM MgCl2 pH* 6.7. The tubulin samples were prepared by removing 
sucrose, Mg2+, and H2O from the storage buffer of a 20 mg sample of frozen tubulin using a 
two-step procedure by chromatography in a drained centrifuge column of Sephadex G-25 
medium (6x1 cm) equilibrated in D2O , 10 mM KPi, 10 μM GTP pH* 7.0 in the cold, followed by 
a second chromatography using another Sephadex G-25 medium column (15x0.9 cm) 
equilibrated in D2O, 10 mM KPi, pH* 7.0. Tubulin was centrifuged and its concentration 
measured as above. Tubulin was diluted to 20 μM and GMPCPP 0.1 mM and 6 mM MgCl2 
(final pH* 6.7) added prior to the drug addition. The samples were then incubated at 37 ºC for 
30 min prior to measurement. 
NMR spectra were then recorded at 298 K (dimeric tubulin samples) or 310 K (polymeric 
tubulin samples) in D2O on a Bruker AVANCE 500 MHz spectrometer equipped with a triple-
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channel cryoprobe. NOESY(43) cross peaks were basically zero at room temperature for both 
docetaxel and discodermolide, and moderately positive at 310 K for free discodermolide.  
For the bound ligands, STD and TR-NOE experiments were performed as described(44), 
using a 30:1 ligand receptor molar ratio for the interaction experiments with non-polymerized 
tubulin -heterodimers, and employing a 15:1 ligand receptor molar ratio for the interaction 
experiments with microtubules. STD experiments were performed with 0.5, 1, and 2 s 
saturation times (by concatenation of 50 ms gaussian pulses separated by 1 ms). TR-NOESY 
experiments with non-polymerized tubulin -heterodimers were performed with mixing times 
of 50, 100, 200, 250 and 300 ms. No purging spin lock period to remove the NMR signals of 
the background macromolecule was employed, since they were basically not observable due 
to the huge size of the receptor. First, line broadening of the ligand protons was monitored 
after the addition of the protein. Strong negative NOE cross peaks were observed, in contrast 
to the free state, indicating binding of the ligands to the non-polymerized tubulin -
heterodimer or microtubule preparation. The theoretical analysis of the TR-NOEs of the ligand 
protons was performed using a full relaxation matrix approach with exchange(45) as 
implemented in the CORCEMA program. Different exchange-rate constants were employed to 
obtain the optimal match between experimental and theoretical results of the intraresidue 
cross peaks of the ligands, which has a relatively fixed geometry. Given the protein/ligand 
ratio, the overall correlation time c for the free state was always set to 0.25 ns, since NOESY 
cross peaks for the free molecule were essentially zero at room temperature and 500 MHz, 
and the c for the bound state was set to 60 ns for non-polymerized tubulin -heterodimers 
(c calculated with HYDROPRO (46)).  
The theoretical STD effects for ligands bound to non-polymerized tubulin -heterodimers 
and microtubules were calculated using the CORCEMA-ST program. The overall correlation 
time c for the free state was always set to 0.25 ns and the average rotational motion 
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correlation time, c, for the bound state was set to 60 ns for non-polymerized tubulin -
heterodimers, and 100 ns for microtubules. An order parameter S2=0.85 was employed to 
account for the fast rotation of the methyl groups, as implemented in CORCEMA-ST.  
In order to fit the experimental STD effects and TR-NOE intensities, off-rate constants 
between 100-200000 s-1 were tested. Optimal agreement was achieved for koff = 100 s-1 in the 
case of microtubules and a combination of Koff = 200000 s-1 for the pore semi-site and Koff = 
125000 s-1 for the luminal binding site, in the case of non-polymerized tubulin -
heterodimers. 
 
Conformational search of ligands. 
The calculations were performed using the MacroModel/Batchmin(47) package (version 9.6) 
and the OPLS2005 all-atom force field as implemented in the program Macromodel 9.6. Bulk 
water solvation was simulated using MacroModel's generalized Born GB/SA continuum 
solvent model(48). The conformational searches were carried out using the torsional sampling 
MCMM search method implemented in the Batchmin program, and 20,000 Monte Carlo step 
runs were performed. Extended non-bonded cutoff distances (a van der Waals cutoff of 8.0 Å 
and an electrostatic cutoff of 20.0 Å) were used. PR conjugate gradient (PRCG) minimization 
(2000 steps) was used in the conformational search. 
 
Docking calculations.  
Docking of the ligands was performed using the AutoDock 4.0 program(49). During an 
AutoDock 4.0 simulation, multiple Lamarckian Genetic Algorithm runs occurred, each one 
providing one predicted binding mode, and cluster analysis was performed at the end of the 
simulation. Atomic coordinates for the ligands were obtained from the NMR data assisted by 
molecular mechanics calculations (see above). The -tubulin dimer coordinates were 
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obtained from the Protein Data Bank 1JFF code. Model tetramer coordinates were kindly 
provided by Prof. M. Botta(28). 
Grids of probe atom interaction energies and electrostatic potential were generated by the 
AutoGrid program present in AutoDock 4.0. Grid spacing of 0.375 Å were used. For each 
calculation, one job of 100 docking runs was performed using a population of 200 individuals 
and an energy evaluation number of 3 × 106. Autodock structures were minimized by using 
Macromodel 9.6, by several steps of Polak-Ribière conjugate gradient (PRCG) until the energy 
gradient become lower than 0.001 kJ Å-1 mol-1. 
Since the scoring function implemented in the Autodock program was not useful to select a 
docking pose compatible with the experimental NMR results, a new scoring function was 
implemented, based on the difference between the experimental and theoretical saturation 
transfer difference (STD) of each ligand's proton (SF-STD). An in-house script which employs 
custom-made programs written in Fortran90 (to be published) was used to perform exhaustive 
file treatment in order to score the docked conformations using the CORCEMA-STD 
program(50) to predict the STD values for a given ligand-receptor complex. Briefly, the output 
files of Autodock were rebuilt and prepared for CORCEMA-STD analysis. In this way, the 
structural information required for each ligand-receptor complex was prepared for calculating 
the theoretical STD. Protein residues located inside a sphere of 8 Å around the ligand were 
considered for the calculations. Finally, the set of docked conformations was ordered 
according to the normalized root-mean-square deviation (NRMSD) values calculated between 
the theoretical and the experimental STD values measured for each proton of the ligand.  
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Figure Legends 
Figure 1.- Chemical structures of docetaxel and discodermolide employed in this study. 
Scatchard plot of binding of discodermolide to non-polymerized -tubulin heterodimer in 10 
mM sodium phosphate, 0.1 mM GTP, pH 7.0 at 25ºC.   
Figure 2.- TR-NOESY spectra (mixing time: 300 ms) of the different ligands in the presence of 
non-polymerized tubulin -heterodimer (D2O, 298 K) A.- docetaxel and B.- discodermolide. 
C.- Red colour: docetaxel conformation when bound to microtubules. Blue colour: docetaxel 
conformation bound to non-polymerized tubulin -heterodimer. 
Figure 3.- A.- Off-resonance NMR experiment (500 MHz) (lower line) and STD spectra (upper 
line) of docetaxel bound to non-polymerized tubulin -heterodimer. B.- Off-resonance NMR 
experiment (500 MHz) (lower line) and STD spectra (upper line) of discodermolide bound to 
non-polymerized tubulin -heterodimer. Protons with higher STD are labeled. C.- Decrease 
of the STD signals of docetaxel with discodermolide concentration. The peak at 7.50 ppm (3´-
Aryl protons) is evaluated. D.- Comparison between the STD profiles of docetaxel bound to 
microtubules (dashed line) and non-polymerized tubulin -heterodimer (solid line). 
Figure 4.- A. Docetaxel binding at the luminal binding site. B. Electron crystallography 
structure of paclitaxel bound to microtubules (pdb code 1JFF).  
Figure 5.- A.- Solutions found for the docking of the microtubule bound form of docetaxel into 
the pore type I of microtubules, the four tubulin heterodimers forming the pore are labeled 1 
(grey), 2 (blue) 3 (green) and 4 (orange), docetaxel pose beween heterodimers 1 and 2 is 
labeled in cyan, while docetaxel pose between heterodimers 1 and 4 is labeled in magenta. B.- 
Docking of the microtubule bound form of discodermolide into pore type I of microtubules, 
discodermolide is labeled in light green.  
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Figure 6.- The comparison between experimental and theoretical STD data (CORCEMA-ST) 
for docetaxel and discodermolide in the presence of microtubules.  A). The experimental STD 
effects (Solid line and circles) for docetaxel, compared with the calculated ones (dashed line 
and squares) for this MSA at the pore of microtubules (blue structure, figure 5A). B. The 
experimental STD effects (solid line and circles) for discodermolide, compared with the 
calculated ones (dashed line and squares) for this MSA (green structure, figure 5B).  
The parameters employed in the CORCEMA calculations were the following; bound correlation 
time 100 ns, koff 100 s-1 and kon 108 s-1 M-1, for diffusion controlled binding. 
Figure 7.- The comparison between experimental and theoretical STD data (CORCEMA-ST) 
for docetaxel and discodermolide in the presence of non-polymerized tubulin -
heterodimers.  A). The experimental STD effects (thick line and black circles) for docetaxel 
compared with the calculated ones for the docking pose at the semi-site at 1 (green circles 
and thin line, koff 105 s-1), and for the docking pose at the luminal site (red circles and thin line, 
koff 105 s-1). The best agreement is found for the combination of these two poses (dashed thick 
line and black squares) using different koff values of 125000 and 200000 s-1, respectively. B) 
The experimental STD effects (solid line and circles) for discodermolide when bound to tubulin 
dimers, compared with the calculated ones when docked at the semi-site at 4 (green circles 
and thin line) and with those estimated when bound at the luminal site (red circles and thin 
line). The best agreement is found for the combination of these two poses (dashed thick line 
and black squares). For discodermolide, the koff values described above were employed for 
each particular case. All CORCEMA calculations for dimeric tubulin employed a bound 
correlation time of 60 ns and a kon value of 108 s-1 M-1, for diffusion-controlled binding. 
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Supplementary Figure 1.- A. Solid line and circles denote docetaxel experimental STD effects when bound to microtubules. Dashed line and 
squares denote CORCEMA-STD calculation with the coordinates of the docetaxel at the pore of microtubules (pink structure, figure 5A). Dotted 
line and triangles denote CORCEMA-STD calculation with the coordinates of the docetaxel at the luminal site of microtubules. B. Solid line and 
circles denote docetaxel experimental STD effects when bound to dimers. Dashed line and squares denote CORCEMA-STD calculation with the 
coordinates of the docetaxel at the semisite pore (with only 4 present) of microtubules (pink structure, figure 5A).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 2.- Expansion of TR-NOESY spectra (mixing time: 300 ms) of docetaxel (Figure 2A) in the presence of non-polymerized 
tubulin -heterodimer (D2O, 298 K). 
Supplementary figure 3.- Expansion of TR-NOESY spectra (mixing time: 300 ms) of discodermolide (Figure 2B) in the presence of non-
polymerized tubulin -heterodimer (D2O, 298 K). 
 
